The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Official Title: A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Study ID: NCT03631407
Brief Summary: This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Honor Health ( Site 0103), Scottsdale, Arizona, United States
California Cancer Associates for Research & Excellence ( Site 0100), Encinitas, California, United States
California Cancer Associates for Research & Excellence ( Site 0102), Fresno, California, United States
Florida Cancer Specialists (South Region) - Research Office ( Site 7001), Fort Myers, Florida, United States
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000), Nashville, Tennessee, United States
Baylor Scott & White Medical Center - Temple ( Site 0104), Temple, Texas, United States
Cross Cancer Institute ( Site 0201), Edmonton, Alberta, Canada
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0204), Montreal, Quebec, Canada
Name: Medical Director
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR